

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)

Published: 07-12-2017

Last updated: 10-01-2025

This study has been transitioned to CTIS with ID 2024-514791-40-00 check the CTIS register for the current data. Based on results from a comparative review (Paoletti 2013), we hypothesize that if the toxicity profile and the PK parameters observed...

| | |
|------------------------------|----------------|
| Ethical review | Approved WMO |
| Status | Recruiting |
| Health condition type | Leukaemias |
| Study type | Interventional |

Summary

ID

NL-OMON49633

Source

ToetsingOnline

Brief title

ESMART

Condition

- Leukaemias
- Miscellaneous and site unspecified neoplasms malignant and unspecified

Synonym

pediatric cancer

Research involving

Human

Sponsors and support

Primary sponsor: Institut Gustave Roussy

Source(s) of monetary or material Support: Ministerie van OC&W, Astra Zeneca, Bristol-Myers Squibb, Celgene Corporation, geringe bijdrage vanuit IGR; free drug van diverse farmaceuten; en eigen fondsen, Novartis

Intervention

Keyword: Children, Molecular abnormalities, Pediatric Cancer, Phase I/II

Outcome measures

Primary outcome

Trial End-points

1. The recommended phase II dose (RP2D) will be defined as the adult recommended dose (adjusted for weight or BSA) if toxicity and PK profiling are similar in children and in adults, or a higher dose, providing it is below or equal to the maximum tolerated dose (MTD).
2. The maximum tolerate dose (MTD) will be defined as the dose associated with or closest to 25% of DLTs in cycle 1.
3. Dose Limiting Toxicities (DLT) will be defined using CTCAE v4.03.
4. Overall response rate (ORR); duration of response (DOR) will be defined as the time period between the first documented response (PR or CR) and the time of progression, according to RECIST v1.1, RANO criteria for patients with HGG, INRC criteria for patients with NB, etc.
5. Duration of response for patients free of progression at the cutoff date will be censored at the last Imaging response scan date;

progression-free survival (PFS) will be defined as the time from treatment initiation until the date of first documented progression or death from any cause. Patients alive and free of progression at the cut-off date will be censored at the last assessment date.

6. Adverse events according to the NCI CTCAE V4.03 in all cycles of treatment.

7. PK parameters, including but not limited to plasma concentration time profiles, AUClast, AUCtau, Cmin, Cmax, Tmax, Clearance, Halflife time.

8. To explore relationship between the molecular profile of the tumor samples, circulating tumor DNA and tumor growth measured as modification of the sum of the diameters of the target lesions over time.

Secondary outcome

NA

Study description

Background summary

The first molecular profiling protocols have been launched in Europe (MOSCATO-01 (Georger 2014), MAPPYACTS, INFORM, iTHER, SM-PAEDS, etc.) determining multiple actionable alterations in pediatric recurrent cancers. Increasingly, stratified approaches are being implemented to enrich clinical trials of molecularly targeted agents and possibly improve outcomes in specific populations i.e. a molecularly enriched/predictive biomarker-driven approach. The diversity and heterogeneity of the detected molecular alterations and the low number of pediatric patients mandate an adapted, innovative trial design for the attributed treatment options in order to satisfy the current unmet medical need. This basket trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe.

Study objective

This study has been transitioned to CTIS with ID 2024-514791-40-00 check the CTIS register for the current data.

Based on results from a comparative review (Paoletti 2013), we hypothesize that if the toxicity profile and the PK parameters observed in children treated at the adult RP2D are similar to those in adults; escalating to the MTD is not necessarily required, unless a dose-activity relationship has been documented in adults. Therefore, for each agent or combination of agents being investigated, there will be two co-primary objectives:

1. Phase I: To define or validate that the adult single agent RP2D of the selected drug or combination of drugs is safe in children/adolescents and equivalent to that seen in adults, in pediatric/adolescent patients with malignancies which are recurrent or refractory to standard therapy.
2. Phase II: To determine the preliminary activity (as measured by tumor response) of these agents in patients harboring specific molecular alterations or tumor types that may be associated with the mechanism of action of these drugs (i.e. molecularly enriched patient cohorts, where possible).

Secondary:

1. To characterize the toxicity profile of the agent(s) in pediatric/adolescent patients.
2. To characterize single or multiple-dose PK of the agent(s).
3. To evaluate the progression free survival and incidence of longterm responders (>6 months).
4. To evaluate whether the response rate is higher in the enriched population as compared to the non-enriched population overall, by targeted treatment and by arm.

Exploratory:

1. To explore, define and/or validate pharmacodynamic (Pd) biomarkers of target inhibition, where possible.
2. To explore relationships between measures of tumor expression of the molecular target(s), circulating tumor DNA and tumor growth.
3. To explore the expression of immunomarker (ARM J)

Study design

This is an international, multi-center, open-label, prospective, phase I/II dose-validation study with a RP2D confirmation part, which is open to being expanded to refine an efficacy assessment for each agent.

Each arm is driven separately with common procedures, quality control and reporting.

For all patients, an extensive molecular analysis of their tumor tissue performed prior to study entry will be requested that will serve to select the

most appropriate arm according to the algorithm provided below.
If no molecular alteration in the pathways selected for this trial are identified, patients may still be enrolled into this study and assigned to a particular treatment arm open for accrual, according to physician discretion, if a strong scientific rationale exists to support the notion that the patient may derive clinical benefit, and if the patient fulfills all other inclusion and no exclusion criteria.

The study is designed to be amended subsequently with new treatment arms in future for up to a maximum of 9 years.

Intervention

Arm A. Ribociclib + Topotecan and Temozolomide

ARM C. AZD1775 + Carboplatin

ARM D. Olaparib + Irinotecan

ARM I: Enasidenib

ARM J: Lirilumab + Nivolumab

Study burden and risks

NA

Contacts

Public

Institut Gustave Roussy

rue Edouard Vaillant 114

Villejuif 94805

FR

Scientific

Institut Gustave Roussy

rue Edouard Vaillant 114

Villejuif 94805

FR

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years)
Adolescents (16-17 years)
Adults (18-64 years)
Children (2-11 years)
Elderly (65 years and older)

Inclusion criteria

1. Patients must be diagnosed with a haematologic or solid tumor malignancy that has progressed despite standard therapy, or for which no effective standard therapy exists.
2. Age < 18 years at inclusion; patients 18 years and older may be included after discussion with the sponsor if they have a pediatric recurrent/refractory malignancy.
3. Patient must have had advanced molecular profiling (i.e. WES/WGS +/- RNAseq) of their recurrent or refractory tumor i.e. at the time of disease progression/relapse; exceptionally patients with advanced molecular profiling at diagnosis may be allowed.
4. Evaluable or measurable disease as defined by standard imaging criteria for the patient*s tumor type (RECIST v1.1, RANO criteria for patients with HGG, INRC criteria for patients with NB, Leukemia criteria, etc.).
5. Performance status: Karnofsky performance status (for patients >12 years of age) or Lansky Play score (for patients <=12 years of age) >= 70%. Patients who are unable to walk because of paralysis or stable neurological disability, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
6. Life expectancy >= 3 months
7. Adequate organ function:
Hematologic criteria (Leukemia patients are excluded from hematological criteria):
 - Peripheral absolute neutrophil count (ANC) >= 1000/ μ L (unsupported)
 - Platelet count >= 100,000/ μ L (unsupported)
 - Hemoglobin >= 8.0 g/dL (transfusion is allowed)Cardiac function:
 - Shortening fraction (SF) >29% (>35% for children < 3 years) and left ventricular ejection fraction (LVEF) >=50% at baseline, as determined by echocardiography (mandatory only for patients

who have received cardiotoxic therapy).

- Absence of QTc prolongation (QTc > 450 msec on baseline ECG, using the Fridericia correction [QTcF formula]) or other clinically significant ventricular or atrial arrhythmia.

Renal and hepatic function:

- Serum creatinine $\leq 1.5 \times$ upper limit of normal (ULN) for age

- Total bilirubin $\leq 1.5 \times$ ULN

- Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) $\leq 2.5 \times$ ULN; aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase/SGOT $\leq 2.5 \times$ ULN except in patients with documented tumor involvement of the liver who must have AST/SGOT and ALT/SGPT $\leq 5 \times$ ULN.

8. Able to comply with scheduled follow-up and with management of toxicity.

9. Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to initiation of treatment.

Sexually active women of childbearing potential must agree to use acceptable and appropriate contraception during the study and for at least 6 months after the last study treatment administration. Sexually active males patients must agree to use condom during the study and for at least 6 months (7 months for arm J) after the last study treatment administration. Acceptable contraception is listed in Appendix 12.

10. For all oral medications patients must be able to comfortably swallow capsules (except for those for which an oral solution is available); nasogastric or gastrostomy feeding tube administration is allowed only if indicated.

11. Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.

12. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.

Exclusion criteria

1. Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease. Patients on stable doses of corticosteroids for at least 7 days prior to receiving study drug may be included.

2. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).

3. Clinically significant, uncontrolled heart disease (including history

of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality, unstable ischemia, congestive heart failure within 12 months of screening)

4. Active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.

5. Presence of any \geq CTCAE grade 2 treatment-related toxicity with the exception of alopecia, ototoxicity or peripheral neuropathy.

6. Systemic anticancer therapy within 21 days of the first study dose or 5 times its half-life, whichever is less.

7. Previous myeloablative therapy with autologous hematopoietic stem cell rescue within 8 weeks of the first study drug dose

8. Allogeneic stem cell transplant within 3 months prior to the first study drug dose. Patients receiving any agent to treat or prevent graft-versus host disease (GVHD) post bone marrow transplant are not eligible for this trial.

9. Radiotherapy (non-palliative) within 21 days prior to the first dose of drug (or within 6 weeks for therapeutic doses of MIBG or craniospinal irradiation).

10. Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.

11. Currently taking medications with a known risk of prolonging the QT interval or inducing Torsades de Pointes (Refer to Appendix 8).

12. Currently taking medications that are mainly metabolized by CYP3A4/5, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters Pgp (MDR1), BCRP, OATP1B1, OATP1B3, OCT1 and OCT2 and have a low therapeutic index that cannot be discontinued at least 7 days or 5 x reported elimination half-life prior to start of treatment with any of the investigational drugs and for the duration of the study (Refer to Appendix 9).

13. Known hypersensitivity to any study drug or component of the formulation.

14. Pregnant or nursing (lactating) females.

15. Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug.

Study design

Design

| | |
|------------------|-------------------------|
| Study phase: | 2 |
| Study type: | Interventional |
| Masking: | Open (masking not used) |
| Control: | Uncontrolled |
| Primary purpose: | Treatment |

Recruitment

| | |
|---------------------------|------------|
| NL | |
| Recruitment status: | Recruiting |
| Start date (anticipated): | 14-05-2018 |
| Enrollment: | 25 |
| Type: | Actual |

Medical products/devices used

| | |
|---------------|-------------------------------|
| Product type: | Medicine |
| Brand name: | AZD1775 |
| Generic name: | AZD1775 |
| Product type: | Medicine |
| Brand name: | Idhifa |
| Generic name: | Enasidenib |
| Product type: | Medicine |
| Brand name: | Kisqali |
| Generic name: | Ribociclib |
| Registration: | Yes - NL outside intended use |
| Product type: | Medicine |
| Brand name: | Lynparza |
| Generic name: | Olaparib |
| Registration: | Yes - NL outside intended use |
| Product type: | Medicine |
| Brand name: | Opdivo |
| Generic name: | Nivolumab |

Ethics review

Approved WMO

Date: 07-12-2017

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

Date: 23-02-2018

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

Date: 20-06-2018

Application type: Amendment

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

Date: 13-07-2018

Application type: Amendment

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

Date: 02-10-2018

Application type: Amendment

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

Date: 16-04-2019

Application type: Amendment

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

Date: 23-08-2019

Application type: Amendment

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

| | |
|--------------------|---|
| Date: | 11-10-2019 |
| Application type: | Amendment |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO | |
| Date: | 14-07-2021 |
| Application type: | Amendment |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO | |
| Date: | 15-07-2021 |
| Application type: | Amendment |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO | |
| Date: | 21-08-2021 |
| Application type: | Amendment |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Not approved | |
| Date: | 25-01-2022 |
| Application type: | Amendment |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO | |
| Date: | 08-02-2022 |
| Application type: | Amendment |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

| Register | ID |
|--------------------|------------------------|
| EU-CTR | CTIS2024-514791-40-00 |
| EudraCT | EUCTR2016-000133-40-NL |
| ClinicalTrials.gov | NCT02813135 |
| CCMO | NL60586.078.17 |